Mirati Therapeutics (formerly MethylGene) is a targeted oncology company developing a pipeline of oncology therapeutics for precisely defined patient populations. Mirati is currently advancing three drug candidates through clinical development for multiple oncology indications.
San Diego, CA and Montreal, Quebec
© 2019 Pappas Capital, LLC. ALL RIGHTS RESERVED.